IMPACT THERAP-B (7630.HK) — Stock Score Summary

IMPACT THERAP-B (7630.HK) has a MoatMap StockRank of 5/100 based on Quality (23/100), Value (34/100), and Momentum (25/100) factor scores. The current signal is STRONG SELL. Impact Therapeutics is a clinical-stage biotech company. It lacks commercialized products, stable cash flows, and the high ROIC characteristics required by our Terry Smith quality lens.

Impact Therapeutics is a clinical-stage biotechnology company dedicated to discovering and developing targeted anti-cancer therapeutics focusing on DNA Damage Response (DDR) pathways. The company is a pioneer in PARP and Wee1 inhibitor development in China, aiming to provide synthetic lethality-based oncology treatments. Its competitive moat is built on a proprietary DDR-focused drug discovery platform and strategic global co-development partnerships.

Key Financial Metrics

Price$4.67
Market Cap$1.4B
Price/Book-7.77
Return on Invested Capital-98.9%
Gross Margin95.9%
Operating Margin-610.4%
Free Cash Flow$-2M

IMPACT THERAP-B operates in the Drug Manufacturers - General industry, part of the Healthcare sector (China).

Frequently Asked Questions

What is IMPACT THERAP-B’s (7630.HK) StockRank?
MoatMap’s StockRank for IMPACT THERAP-B (7630.HK) is 5/100, with a Strong Sell signal. It is a composite of Quality (23), Value (34), and Momentum (25) factor ranks across MoatMap’s 19,000+ stock universe.
Does IMPACT THERAP-B have an economic moat?
IMPACT THERAP-B (7630.HK) has a Quality factor score of 23/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is IMPACT THERAP-B a buy, hold, or sell?
MoatMap’s current signal for IMPACT THERAP-B (7630.HK) is Strong Sell, based on a StockRank of 5/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is IMPACT THERAP-B in?
IMPACT THERAP-B (7630.HK) operates in the Healthcare sector, specifically the Drug Manufacturers - General industry (China).
Browse all ranked stocks7630.HK deep dive reportAI ChampionsHow we score stocksSense-check another stock